- Home
- MRSN vs CCEL Comparison
MRSN vs CCEL Comparison
Compare MRSN & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- CCEL
- Stock Information
- Founded
- MRSN 2001
- CCEL 1989
- Country
- MRSN United States
- CCEL United States
- Employees
- MRSN N/A
- CCEL N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- MRSN Health Care
- CCEL Health Care
- Exchange
- MRSN Nasdaq
- CCEL Nasdaq
- Market Cap
- MRSN 34.0M
- CCEL 39.9M
- IPO Year
- MRSN 2017
- CCEL 1997
- Fundamental
- Price
- MRSN $6.75
- CCEL $4.90
- Analyst Decision
- MRSN Strong Buy
- CCEL Strong Buy
- Analyst Count
- MRSN 5
- CCEL 1
- Target Price
- MRSN $5.75
- CCEL $8.50
- AVG Volume (30 Days)
- MRSN 130.5K
- CCEL 8.1K
- Earning Date
- MRSN 08-12-2025
- CCEL 07-15-2025
- Dividend Yield
- MRSN N/A
- CCEL 12.45%
- EPS Growth
- MRSN N/A
- CCEL N/A
- EPS
- MRSN N/A
- CCEL N/A
- Revenue
- MRSN $34,006,000.00
- CCEL $31,988,783.00
- Revenue This Year
- MRSN N/A
- CCEL $2.49
- Revenue Next Year
- MRSN $1.03
- CCEL $0.95
- P/E Ratio
- MRSN N/A
- CCEL N/A
- Revenue Growth
- MRSN N/A
- CCEL 1.10
- 52 Week Low
- MRSN $6.47
- CCEL $4.68
- 52 Week High
- MRSN $70.75
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- MRSN 38.74
- CCEL 47.88
- Support Level
- MRSN $6.55
- CCEL $4.80
- Resistance Level
- MRSN $10.25
- CCEL $5.24
- Average True Range (ATR)
- MRSN 0.70
- CCEL 0.27
- MACD
- MRSN -0.20
- CCEL 0.01
- Stochastic Oscillator
- MRSN 5.41
- CCEL 35.68
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.